Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Infectious Diseases

• Publication date

  2008-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/524669PMID 18171251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

  2007cited by this paper
• Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

  2007cited by this paper
• Altered Pharmacokinetics of Voriconazole in a Patient with Liver Cirrhosis

  2007cited by this paper
• Analysis of Loss of Heterozygosity in Adult Patients with De Novo Acute Myeloid Leukemia and Normal Karyotype.

  2006cited by this paper
• Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.

  2006cited by this paper
• Treatment options of invasive fungal infections in adults.

  2006cited by this paper
• Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints

  2006cited by this paper
• Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring.

  2006cited by this paper
• Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods

  2006influential reference
• Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection.

  2006cited by this paper
• Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities

  2006cited by this paper
• Voriconazole Therapeutic Drug Monitoring

  2006cited by this paper
• Pharmacology of Systemic Antifungal Agents

  2006cited by this paper
• In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.

  2005cited by this paper
• Interaction between voriconazole and tacrolimus in a kidney-transplanted patient.

  2005cited by this paper
• Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients

  2005cited by this paper
• Improved outcome in central nervous system aspergillosis, using voriconazole treatment.

  2005cited by this paper
• Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

  2005cited by this paper
• Susceptibility of Filamentous Fungi to Voriconazole Tested by Two Microdilution Methods

  2005cited by this paper
• Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

  2005cited by this paper
• How does a patient maximally benefit from anti-infective chemotherapy?

  2004cited by this paper
• Guidelines for treatment of candidiasis.

  2004cited by this paper
• Adverse reactions to voriconazole.

  2004cited by this paper
• Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration

  2004cited by this paper
• Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.

  2003cited by this paper
• In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model

  2003cited by this paper
• Voriconazole treatment for less-common, emerging, or refractory fungal infections.

  2003cited by this paper
• Safety of voriconazole and dose individualization.

  2003cited by this paper
• Voriconazole: A New Triazole Antifungal Agent

  2003cited by this paper
• Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

  2002cited by this paper
• Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

  2002influential reference
• Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

  2002cited by this paper
• Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

  2002cited by this paper
• Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

  2002cited by this paper
• The safety of voriconazole.

  2002cited by this paper
• Efficacy of Voriconazole in Treatment of Murine Pulmonary Blastomycosis

  2001cited by this paper

• OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES

  2026cites this paper
• Bioanalytical determination of azole antifungals for mycetoma treatment in biological fluids: Advances, challenges, and implementation strategies

  2026cites this paper
• Improving voriconazole therapeutic drug monitoring-guided dosing through a clinical decision support system: enhancing antifungal stewardship.

  2026cites this paper
• Phaeohyphomycoses in kidney transplant recipients: A 10-year retrospective study from the French West Indies

  2026cites this paper
• Unravelling Voriconazole's Hepatic Metabolism: A Narrative Review on Factors Impacting Voriconazole‐N‐Oxide Exposure

  2026cites this paper
• Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm

  2025cites this paper
• Voriconazole Steady-State Trough Concentrations and Clinical Outcomes in Patients with Talaromycosis

  2025influential citation
• Prospective Analysis of Factors Influencing Inter-Individual Variation in Trough Plasma Voriconazole Concentrations in Older Patients-Impact of High α1-Acid Glycoprotein Levels.

  2025cites this paper
• Suivi thérapeutique pharmacologique des antifongiques azolés

  2025cites this paper
• The Predictive Value of Initial Trough Concentration of Voriconazole and Procalcitonin in Hepatotoxic Adverse Events

  2025influential citation
• Optimizing Voriconazole Dosing in Extremely Premature Infants With Aspergillus Infections.

  2025cites this paper
• Risk factors for voriconazole-associated hepatotoxicity in patients with liver dysfunction: a retrospective nested case–control study

  2025cites this paper
• Pharmacogenetics of steady-state metabolism, pharmacokinetics, and adverse effects of voriconazole in healthy participants.

  2025cites this paper
• Evaluating the impact of infectious disease pharmacy services on voriconazole dose individualization in pediatric oncology.

  2025cites this paper
• Aspergillosis: A comprehensive review of pathogenesis, drug resistance, and emerging therapeutics

  2025cites this paper
• A Real-world Pharmacovigilance Study Of FDA Adverse Event Reporting System (FAERS) Events For Gender Of Voriconazole Drugs

  2025cites this paper
• Management of Invasive Pulmonary Aspergillosis in Intensive Care Units: Guidelines From the Fungal Infection Network of Switzerland (FUNGINOS)

  2025cites this paper
• Toward Genotype-Informed Dosing of Voriconazole: Head-to-Head Simulations Across CYP2C19 Phenotypes Using Population Pharmacokinetic Models

  2025influential citation
• Pharmacokinetic novelties of isavuconazole. Use in special situations.

  2025cites this paper
• Study of the Outcome of Invasive Fungal Infection Complicating ICU Patients of Community Acquired Pneumonia of A Tertiary Care Hospital of Eastern India – A Randomised Controlled Trial

  2025cites this paper
• Personalizing voriconazole dosing in Chinese hematological patients: CYP2C19 phenotype and albumin-bilirubin grade as key predictors of trough concentrations

  2025cites this paper
• Establishment and validation of a predictive nomogram for voriconazole-associated liver injury in lung transplant patients

  2025cites this paper
• Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations

  2025cites this paper
• Chinese population may require further venetoclax dose reduction beyond guidelines when combined with voriconazole: real-world evidence from China

  2025cites this paper
• Insights on antifungal therapeutic drug monitoring from infectious diseases physicians and hospital‐based pharmacists: A focus group analysis

  2025cites this paper
• Isavuconazole therapeutic drug monitoring and association with adverse events

  2025cites this paper
• S1-Leitlinie: Diagnostik und Therapie der invasiven pulmonalen Aspergillose bei kritisch kranken/intensivpflichtigen Patienten

  2025cites this paper
• Therapeutic drug monitoring of antifungal therapies: do we really need it and what are the best practices?

  2024cites this paper
• Mass spectrometric methods for evaluation of voriconazole avian pharmacokinetics and the inhibition of its cytochrome P450-induced metabolism

  2024cites this paper
• Assessment of Inter-Individual Pharmacokinetic Variability of Voriconazole Based on Bile Salt Disparities using POP-PK Modeling

  2024cites this paper
• Stability and Analytical Characterization of Voriconazole as Measured by Immunoassay.

  2024cites this paper
• Infections fongiques en réanimation

  2024cites this paper
• Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome

  2024cites this paper
• Therapeutic Drug Monitoring of Voriconazole in Critically Ill Pediatric Patients: A Single-Center Retrospective Study

  2024cites this paper
• Biosynthesis of ergosterol as a relevant molecular target of metal-based antiparasitic and antifungal compounds

  2024cites this paper
• Impact of Anti-Mycotic Drugs on the Osteogenic Response of Bone Marrow Mesenchymal Stem Cells In Vitro

  2024cites this paper
• Antifungal drug penetration in soft tissue abscesses: a comparative analysis

  2024cites this paper
• Bioequivalence study of voriconazole for intravenous infusion in healthy Chinese subjects under fasting conditions.

  2024cites this paper
• Association of procalcitonin with voriconazole concentrations: a retrospective cohort study

  2024cites this paper
• Evaluation of voriconazole therapeutic drug monitoring in malignant hematology patients

  2024cites this paper
• Prevention and Treatment of Cancer-Related Infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• Enhancing voriconazole therapy in liver dysfunction: exploring administration schemes and predictive factors for trough concentration and efficacy

  2024influential citation
• Voriconazole-induced central nervous system toxicity: a pharmacovigilance study based on FDA adverse event reporting system (FAERS) database

  2024cites this paper
• Relationship between Early-onset Adverse Events and Drug Plasma Concentrations in Patients Receiving Oral Voriconazole

  2024cites this paper
• Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections

  2024influential citation
• Drug-induced psychotic syndrome

  2024cites this paper
• Blastomycosis.

  2024cites this paper
• A Perspective Study on Therapeutic Drug Monitoring of Voriconazole in Pediatric Patients with Hematologic Disorders

  2024cites this paper
• Update on therapeutic approaches for invasive fungal infections in adults

  2024influential citation
• Myelodysplastic syndrome-like response after voriconazole treatment of systemic lupus erythematosus complicated with fungal infection: a case report

  2023cites this paper
• Therapeutic Drug Monitoring of Voriconazole in Patients with End-Stage Liver Disease

  2023cites this paper
• Antifungal Therapies for Aspergillus spp.: Present and Future

  2023cites this paper
• Assessing the safety profile of voriconazole use in suspected COVID-19-Associated pulmonary aspergillosis - A two-centre observational study.

  2023cites this paper
• The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals

  2023cites this paper
• Potential Implication of Azole Persistence in the Treatment Failure of Two Haematological Patients Infected with Aspergillus fumigatus

  2023cites this paper
• Enhancing the identification of voriconazole-associated hepatotoxicity by targeted metabolomics.

  2023cites this paper
• Antifungal drugs

  2023cites this paper
• Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients

  2023cites this paper
• Tissue Expander for Pediatric Scalp Reconstruction Complicated by Fungal Infection With Aspergillus terreus.

  2023cites this paper
• Higher Weight-Based Doses Are Required to Achieve and Maintain Therapeutic Voriconazole Serum Trough Concentrations in Children.

  2023cites this paper
• Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists

  2023cites this paper
• Systemic lupus erythematosus associated with development of macrophage activation syndrome and disseminated aspergillosis

  2023cites this paper
• The Future of (radio)-labeled Compounds in Research and Development of the Life Science Industry.

  2023cites this paper
• Infecciones fúngicas en pediatría

  2023cites this paper
• Disseminated Aspergillosis in a Patient With Neurosarcoidosis: Persistent Contrast Enhancement in CNS Despite Prolonged Antifungal Treatment: A Case Report

  2023cites this paper
• Breakthrough Invasive Sinusitis by Hormographiella aspergillata in a Neutropenic Patient Receiving Voriconazole Therapy: A Case Report and Review of Breakthrough H. aspergillata Infections

  2023cites this paper
• Combatting antifungal resistance: Paradigm shift in the diagnosis and management of onychomycosis and dermatomycosis

  2023cites this paper
• Infections fongiques en pédiatrie

  2023cites this paper
• Pulmonary Histoplasmosis: A Clinical Update

  2023cites this paper
• Blastomycosis: A Review of Mycological and Clinical Aspects

  2023cites this paper
• [Clinical Analysis of Voriconazole Concentrations in Cerebrospinal Fluid and Blood in Patients with Ryptococcal Meningitis].

  2023cites this paper
• Systemic Antifungal Therapy for Invasive Pulmonary Infections

  2023cites this paper
• Therapeutic drug monitoring guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised cross-over clinical trial.

  2023cites this paper
• Evaluation of Pharmacokinetics and Safety With Bioequivalence of Voriconazole Injection of 2 Formulations in Chinese Healthy Volunteers: Bioequivalence Study

  2023cites this paper
• A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation

  2023cites this paper
• Optimization of Antimicrobial Stewardship Programs Using Therapeutic Drug Monitoring and Pharmacokinetics–Pharmacodynamics Protocols: A Cost-Benefit Review

  2023cites this paper
• Comparison of ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and enzyme-multiplied immunoassay technique (EMIT) for quantification of voriconazole plasma concentration from Chinese patients

  2023cites this paper
• Therapeutic Drug Monitoring of Voriconazole in Children with Hematologic Malignancy and Invasive Fungal Infections: An RCT from a Tertiary Care Centre in India.

  2023cites this paper
• Factors Influencing Blood Concentration of Voriconazole and Therapeutic Drug Monitoring in Patients with Child–Pugh Class C Cirrhosis

  2023cites this paper
• New Perspectives on Antimicrobial Agents: Isavuconazole

  2022cites this paper
• Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients

  2022cites this paper
• Associated microbiota and treatment of severe fever with thrombocytopenia syndrome complicated with infections

  2022cites this paper
• The Safety, Toleration, and Pharmacokinetics of Two Intravenous Voriconazole Formulations in Healthy Chinese Volunteers After Increasing Dose Administrations

  2022cites this paper
• Pharmacogenetic Analysis of Voriconazole Treatment in Children

  2022cites this paper
• Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax

  2022cites this paper
• Novel Dioxolane Ring Compounds for the Management of Phytopathogen Diseases as Ergosterol Biosynthesis Inhibitors: Synthesis, Biological Activities, and Molecular Docking.

  2022cites this paper
• Sino-Orbital Aspergillosis in a Kidney Transplant Recipient

  2022cites this paper
• Difenoconazole causes spleen tissue damage and immune dysfunction of carp through oxidative stress and apoptosis.

  2022cites this paper
• Azole Therapeutic Drug Monitoring and its Use in the Management of Invasive Fungal Disease

  2022cites this paper
• Voriconazole-Induced Hepatotoxicity Concise up-to-date review

  2022cites this paper
• Decrease of voriconazole trough levels during therapy with enteral nutrition: a case report

  2022cites this paper
• Coccidioidomycosis: A Contemporary Review

  2022cites this paper
• Voriconazole in hematopoietic stem cell transplantation and cellular therapies: Real-world usage and therapeutic level attainment at a major transplant center.

  2022cites this paper
• Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children

  2022cites this paper
• Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

  2022cites this paper
• Pulmonary aspergillosis: diagnosis and treatment

  2022cites this paper
• Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases

  2022cites this paper
• Optimizing antifungal prophylaxis in allogeneic stem cell transplantation: A cohort study of two different approaches

  2022cites this paper
• Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold – A Retrospective Cohort Study

  2022cites this paper
• Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis

  2022cites this paper